Skip to main content
Equibles
CTKB logo

CTKB · Cytek Biosciences, Inc. · Financials

Track CTKB — free

Use CTKB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CTKB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.61 -0.13 (-2.64%)
Russell 2000 member Rebalance outlook locked
Market Cap
$600.52M
Shares
129.98M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →
Revenue
$201.49M +0.5%
FY2025 Revenue FY2020–FY2025
Net Income
-$66.54M -1005.3%
FY2025 Net Income FY2020–FY2025
Gross Margin
51.84% -3.6pp
FY2025 Gross Margin FY2020–FY2025
Operating Margin
-20.04% -9.8pp
FY2025 Operating Margin FY2020–FY2025
Diluted EPS
-$0.09 -550%
FY2023 Diluted EPS FY2020–FY2023
Operating Cash Flow
-$4.69M -118.5%
FY2025 Operating Cash Flow FY2020–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 (G) TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
$207M – $212M $206.71M $201.49M $200.45MG $193.02M $2.96MG $2.18M $710K
— $96.68M $97.03M $89.35M $83.59M $63.06M $48.81M $41.13M
— $110.03M $104.46M $111.11M $109.43M $100.97M $79.14M $51.71M
— — 51.84% 55.43% 56.69% 3407.83% 3628.79% 7283.1%
— $37.26M $36.47M $39.4M $44.15M $34.86M $24.44M $13.69M
— $49.62M $49.44M $49.11M $49.15M $33.23M $24.71M $14.99M
— $67.8M $58.94M $43.11M $43.97M $34.69M $20.84M $9.37M
— $3.7M $3.7M $3.7M $3.2M $800K $300K $71K
— $7.69M $7.58M $7.21M $6.05M $2.49M $1.24M $603K
— $154.68M $144.84M $131.63M $137.27M $102.78M $69.99M $38.05M
— -$44.65M -$40.38M -$20.52M -$27.85M -$1.8M $9.16M $13.66M
— — -20.04% -10.24% -14.43% -60.88% 419.85% 1923.8%
— -$36.96M -$32.81M -$13.31M -$21.8M $688K $10.4M $14.26M
— $312K $474K -$5.24M $2.07M $2.57M $1.74M $333K
— $2.76M $2.22M $5.12M $6.41M $4.62M $49K $110K
— $3.83M $10.54M $14.82M $12.14M $3.06M -$3.22M $771K
— — -$29.84M -$5.7M -$15.71M $1.26M $5.94M $14.43M
— $39.76M $36.7M $320K -$3.56M -$1.22M $2.91M -$4.98M
— -$80.58M -$66.54M -$6.02M -$12.15M $2.48M $3.03M $19.41M
— — -33.02% -3% -6.29% 83.83% 138.79% 2733.94%
— — $0 $0 $0 -$92K $26K $0
— -$80.58M -$66.54M -$6.02M -$12.15M $2.58M $0 $3.22M
— -$77.8M -$64.31M -$4.73M -$12.73M $890K $3.86M $19.62M
USD/shares — — — — -$0.09 $0.02 $0.00 $0.11
USD/shares — — — — -$0.09 $0.02 $0.00 $0.10
shares — — 127.75M 130.61M 135.28M 134.51M 76.74M 29.13M
shares — — 127.75M 130.61M 135.28M 138.56M 81.54M 32.6M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2025: $80.84M in buybacks.

Debt Profile

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Debt data is being processed. Please check back later.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 2.37×
EV/EBIT
—
Peer median 22.69×
P/E (TTM)
—
Peer median 23.74×

Peer medians compare against the 71 similar-size Medical Devices companies (of 150 listed).

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025 FY2024 FY2023 FY2022
Reportable Segment $201,493,000 $200,453,000 $193,015,000 $164,036,000

By Geography (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
United States $95,250,000 $92,610,000 $102,085,000 $94,592,000 $72,724,000 $55,477,000
EMEA $55,883,000 $62,341,000 $53,178,000 $43,958,000 $36,967,000 $25,912,000
Asia Pacific $41,080,000 $35,770,000 $31,598,000 $22,523,000 $16,078,000 $10,740,000
China $20,500,000 — — — — —
Other $9,280,000 $9,732,000 $6,154,000 $2,963,000 $127,950,000 $92,839,000

By Product & Service (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Product $144,233,000 $153,263,000 $156,717,000 $148,600,000 $119,519,000 $85,283,000
Service $57,260,000 $47,190,000 $36,298,000 $15,436,000 $8,431,000 $7,556,000
Key facts CIK 1831915 CUSIP 23285D109 13F (30d) 100 filings 99 filers Visit website Investor relations